

Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy

Wenpeng Cao^{1,2,*}, Jinzhi Lan^{3,*}, Chujiao Hu^{4,5,6}, Jinping Kong⁴, Limin Xiang⁴, Zhixue Zhang⁴, Yating Sun⁴, Zhirui Zeng⁴, Shan Lei⁴

¹Department of Anatomy, School of Basic Medicine, Guizhou Medical University, Guiyang, Guizhou 550025, China

²Key Laboratory of Human Brain Bank for Functions and Diseases of Department of Education of Guizhou, Guizhou Medical University, Guiyang, Guizhou 550025, China

³Center for Tissue Engineering and Stem Cell Research, Guizhou Medical University, Guiyang, Guizhou 550004, China

⁴Department of Physiology, School of Basic Medicine, Guizhou Medical University, Guiyang, Guizhou 550025, China

⁵State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, Guizhou 550025, China

⁶Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guiyang, Guizhou 550025, China

*Equal contribution

Correspondence to: Wenpeng Cao, Zhirui Zeng, Shan Lei; **email:** caowenpeng@gmc.edu.cn, zengzhirui@gmc.edu.cn, leishan@gmc.edu.cn

Keywords: immunity, risk model, glioma, TERT promoter mutation, immune checkpoint blockade therapy

Received: September 1, 2023

Accepted: December 26, 2023

Published: March 18, 2024

Copyright: © 2024 Cao et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The telomerase reverse transcriptase promoter (TERTp) is frequently mutated in gliomas. This study sought to identify immune biomarkers of gliomas with TERTp mutations. Data from TCGA were used to identify and validate survival-associated gene signatures, and immune and stromal scores were calculated using the ESTIMATE algorithm. High stromal or immune scores in patients with TERTp-mutant gliomas correlated with shorter overall survival compared to cases with low stromal or immune scores. Among TERTp-mutant gliomas with both high immune and high stromal scores, 213 commonly shared DEGs were identified. Among 71 interacting DEGs representing candidate hub genes in a PPI network, HOXC6, WT1, CD70, and OTP showed significant ability in establishing subgroups of high- and low-risk patients. A risk model based on these 4 genes showed strong prognostic potential for gliomas with mutated TERTp, but was inapplicable for TERTp-wild-type gliomas. TERTp-mutant gliomas with high-risk scores displayed a greater percentage of naïve B cells, plasma cells, naïve CD4 T cells, and activated mast cells than low-risk score gliomas. TIDE analysis indicated that immune checkpoint blockade (ICB) therapy may benefit glioma patients with TERTp mutations. The present risk model can help predict prognosis of glioma patients with TERTp mutations and aid ICB treatment options.

INTRODUCTION

Among all intracranial malignant neoplasms, gliomas are the most common and aggressive forms of primary

brain tumors [1, 2]. The poor survival outcome of glioma patients is related to the limited efficacy of current treatment options, including surgery, radiotherapy, and chemotherapy [3]. Multiple genetic anomalies are

commonly present in gliomas, including IDH mutations [4], 1p/19q co-deletion [5], and TERT promoter (TERTp) mutations [6]. TERTp mutations are among the most common somatic non-coding mutations in human cancers, driving cancer cell immortalization and tumor progression by reactivating telomerase activity [7, 8]. Indeed, TERTp mutations occur in more than half of all glioma grades, and in over 80% of WHO grade IV gliomas (i.e., glioblastoma, GBM), the most lethal glioma type [9]. While the prognostic significance of TERTp mutations is still equivocal and may depend on concurrent mutations [10], there is an urgent interest in developing therapeutic strategies to inhibit TERT activity in cancer cells [11]. TERTp mutations are associated with poor survival in patients with gliomas [12], and thus different treatment strategies may be needed for patients with wild-type and mutant TERTp. Therefore, the identification of biomarkers associated with TERTp mutations may be helpful to guide glioma treatment.

In the current study, the TCGA database was searched to identify biomarkers associated with TERTp mutations in patients with gliomas. After analysis of immune and stromal cell distributions in TERTp-mutant gliomas, bioinformatics methods and COX regression techniques were applied to identify differentially regulated genes associated with survival. From these data, a risk model based on 4 immune-related genes was developed and applied to differentiate low-risk from high-risk patients and to construct a nomogram to predict overall survival. The present risk model will hopefully serve to guide the treatment of gliomas containing mutations in the TERT promoter.

RESULTS

High stromal/immune scores predict lower overall survival in glioma patients with TERTp mutations

After retrieving gene expression profiles from glioma patients with TERTp mutations in TCGA, we evaluated the association between immune and stromal scores, obtained with the ESTIMATE algorithm, and overall survival (OS). A lower OS rate was detected after Kaplan-Meier survival analysis for gliomas with high immune (Figure 1A) and stromal (Figure 1B) scores. We next conducted comparative gene expression analysis between the high and low immune/stromal groups. A total of 245 genes were upregulated, whereas 120 genes were downregulated, in TERTp-mutated glioma tissues from the high, compared to the low, immune group (Figure 1C, 1D). In turn, 181 upregulated genes and 38 downregulated genes were detected in glioma tissues in the high, compared to the low, stromal group (Figure 1E, 1F). Upon comparative analysis of TERTp-mutant

glioma tissues with high stromal and high immune scores, a total of 213 DEGs (175 co-upregulated and 38 co-downregulated ones; Figure 1G, 1H) were found to be shared among the two groups (Supplementary Table 1).

After constructing a PPI network, we identified 71 genes involved in gene-to-gene interactions (Figure 1I). Genes related to stromal and immune scoring in TERTp-mutant gliomas were identified as candidate hub genes. KEGG enrichment analysis revealed that these candidate hub genes interact with cytokines and cytokine receptors, showing enrichment in ‘cytokine-cytokine receptor interaction’, ‘T cell receptor signaling pathway’, ‘allograft rejection’, ‘primary immunodeficiency’, ‘transcriptional misregulation in cancer’, ‘systemic lupus erythematosus’, ‘chemokine signaling pathway’, and ‘Th17 cell differentiation’ (Figure 1J). Gene Ontology (GO)-BP enrichment analysis based on cell adhesion molecule ontology revealed that these candidate hub genes are enriched in pattern specification processes, regionalization, and anterior/posterior pattern specification (Figure 1K). GO-CC enrichment analysis showed enrichment on the external surface of plasma membrane for these candidate hub genes (Figure 1L). Based on GO-MF enrichment analysis, candidate hub genes are enriched in DNA-binding transcription activator activity, enhancer sequence-specific DNA binding, enhancer binding, receptor ligand activity, and cytokine activity (Figure 1M).

Construction of an immune signature for glioma patients with TERTp mutations

Next, we assessed the association between high immune/high stromal score-related DEGs identified in TCGA-glioma patients with TERTp mutations and survival data. Based on univariate Cox regression, 73 of 213 DEGs were associated with survival (Supplementary Table 2). Upon further analysis using LASSO and Cox regression analyses, seven additional DEGs, including HOXC6, HOXA10, EOMES, WT1, HOXC10, CD70, OTP retained significant associations with overall survival (Figure 2A, 2B). Based on the above analysis, a risk model associated with mutant TERTp in glioma was constructed using gene expression data for HOXC6, WT1, CD70, and OTP, as well as survival data from the TCGA. For each patient, the risk score was calculated as: $\text{HOXC6} \times 0.211 + \text{WT1} \times 0.312 + \text{CD70} \times 0.511 + \text{OTP} \times 0.299$ (Figure 2C).

Risk model validation

To validate the applicability of the risk model described above, glioma patients with TERTp mutations were

divided into high-risk and low-risk groups in a training cohort (Figure 3A). In the latter, high-risk scores were associated with lower OS rates (Figure 3B). After ROC analysis, the AUCs for predicting survival one year, three years, and five years after diagnosis were 0.867, 0.845, and 0.85, respectively (Figure 3C–3E).

Further analysis indicated a higher mortality risk for patients with high-risk scores (Figure 3F). As shown in Figure 3G, HOXC6, WT1, CD70, and OTP were highly expressed in high-risk vs. low-risk glioma samples. A prognostic risk model and a moderate risk score constructed in the TCGA test cohort were used to




Figure 1. Effect of stromal and immune scores on survival of patients with TERTp-mutant gliomas. (A) Kaplan-Meier survival analysis of patients in the high and low immune score groups. (B) Kaplan-Meier survival analysis of patients in the high and low stromal score groups. (C) Volcano plot showing differential gene expression for the high and low immune groups. (D) Heat map depicting differential gene expression between TERTp-mutant gliomas in the high and low immune groups. (E) Volcano plot showing differential gene expression for TERTp-mutant gliomas in the high and low stromal groups. (F) Heat map showing DEGs between TERTp-mutant gliomas in the high and low stromal groups. (G) Venn diagram of upregulated genes in the high stromal and immune groups. (H) Venn diagram of downregulated genes in the high stromal and immune groups. (I) PPI network constructed using 71 overlapping DEGs while removing isolated genes. Genes in the PPI network was set as candidate hub genes. (J) Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of candidate hub genes. (K) GO-Biological process (BP) analysis of candidate hub genes. (L) GO-Cellular component (CC) analysis of candidate hub genes. (M) GO-Molecular function (MF) analysis of candidate hub genes.

categorize glioma cases as high-risk or low-risk (Figure 3H). In this test cohort, the OS rate of glioma patients with high-risk scores was also shorter (Figure 3I). According to ROC curves, AUCs of 0.884, 0.986, and 0.99 were respectively obtained for 1-year, 3-year, and 5-year OS (Figure 3J–3L). It was also observed in the test cohort that patients with high-risk scores died more frequently (Figure 3M). As shown in Figure 3N, HOXC6, WT1, CD70, and OTP expression was upregulated in glioma tissues from patients with high-risk scores. This evidence suggests that the proposed risk model is useful for predicting the prognosis of glioma patients with TERTp mutations.

Applicability of the risk model in TCGA-glioma patients with wild-type TERTp

In the TCGA-glioma cohort, high-risk and low-risk TERTp-wild-type gliomas were classified based on median risk scores (Figure 4A). Survival analysis indicated that patients with high-risk scores lived shorter than those with low-risk scores (Figure 4B). On ROC analysis, AUCs of 0.818, 0.619, and 0.636, predictive, respectively, of 1-year, 3-year, and 5-year survival, were recorded for glioma patients with wild-type TERTp (Figure 4C–4E). There was no significant difference in mortality between high-risk patients and




Figure 2. Hub genes selected to construct the risk model. (A, B) LASSO analysis for hub genes associated with the survival rate of glioma patients with TERTp mutations. (C) Multivariate Cox regression analysis of HOXC6, WT1, CD70, and OTP. These four genes were used to construct the risk model.

those at low risk (Figure 4F). HOXC6, WT1, CD70, and OTP expression was elevated in glioma tissues from high-risk score patients carrying wild-type TERTp (Figure 4G). However, in patients with wild-type TERTp-wild-type gliomas, the HOXC6-WT1-CD70-OTP risk models did not predict survival, and may thus be specific to glioma cases with TERTp mutations.

A nomogram based on a 4-gene immune signature has prognostic ability in glioma patients with TERTp mutations

Based on multivariate Cox regression analysis, the immune signature created using HOXC6, WT1, CD70, and OTP represented an independent prognostic factor




Figure 3. Validation of the applicability of the risk model in patients with TERTp-mutant gliomas. (A) Patients with TERTp-mutant gliomas in the training cohort were divided into high-risk and low-risk groups based on the median risk score. (B) Survival differences between patients in the high- and low-risk scoring groups in the training cohort. (C–E) Diagnostic value of risk models for 1-year, 3-year, and 5-year survival in the training cohort. (F) Survival time as a function of risk score for patients in the training cohort. Green dots represent live cases, and red dots represent dead cases. (G) Heatmap depicting expression levels of HOXC6, WT1, CD70, and OTP in glioma samples in the high-risk and low-risk score groups in the training cohort. (H) Patients with TERTp-mutant gliomas in the test cohort were divided into high-risk and low-risk groups based on the median risk score. (I) Survival differences between patients in the high- and low-risk score groups in the test cohort. (J–L) Diagnostic value of risk models for 1-year, 3-year, and 5-year survival for patients in the test cohort. (M) Survival time as a function of risk score for patients in the high-risk and low-risk scoring groups in the test cohort. Green dots represent living cases, and red dots represent dead cases. (N) Heatmap depicting expression levels of HOXC6, WT1, CD70, and OTP in glioma patients in the high-risk and low-risk scoring groups of the test cohort.

for glioma patients with TERTp mutations. This is evidenced in a column line plot based on signature risk scores and clinical features (Figure 5A), which showed excellent prognostic value for 1-, 3-, and 5-year survival (Figure 5B).

Analysis of tumor-infiltrating immune cell types and predicted response to immune checkpoint blockade therapy in glioma patients with TERTp mutations

Research has demonstrated that immune cells infiltrating TERTp-mutant gliomas play a significant

role in disease progression. Thus, CIBERSORT was used to analyze the distribution of 22 infiltrating immune cell types in high-risk and low-risk glioma patients with TERTp mutations (Figure 6A, 6B). Compared to low-risk gliomas, high-risk gliomas showed higher proportions of naïve B-cells, plasma cells, naïve CD4 T-cells, and activated mast cells, and lower proportions of memory B cells, resting memory CD4 T cells, regulatory T cells, resting NK cells, M0 and M2 macrophages, dendritic cells, and neutrophils (Figure 6C). In addition, TIDE analysis indicated that immune checkpoint blockade (ICB) may be an effective




Figure 4. Validation of the applicability of the risk model in TCGA-glioma patients with wild-type TERTp. (A) Patients with TERTp-wild-type glioma in the TCGA database were divided into high-risk and low-risk groups based on the median risk score. (B) Survival differences between patients in the high-risk and low-risk groups. (C–E) Diagnostic value of risk models for 1-year, 3-year, and 5-year survival rates. (F) Survival time as a function of risk score for glioma patients with wild-type TERTp in the high-risk and low-risk groups. Green dots represent living cases, and red dots represent dead cases. (G) Heatmap depicting expression levels of HOXC6, WT1, CD70, and OTP in gliomas from patients with wild-type TERTp in the high-risk and low-risk groups.




Figure 5. Construction of a nomogram based on a 4-gene signature risk score and clinical characteristics. (A) Proposed nomogram, incorporating age, gender, glioma grade, and risk score. **(B)** Efficiency of the nomogram in predicting 1-year, 3-year, and 5-year survival for patients with TERTp-mutant gliomas.




Figure 6. Immunological characteristics of TERTp-mutant gliomas in TCGA. (A, B) Expression matrices showing proportions and expression patterns of 22 tumor-infiltrating immune cell types in TCGA-glioma tissues from patients with TERTp mutations in the high- and low-risk groups. **(C)** Profiling of tumor-infiltrating immune cells in TERTp-mutations-type glioma tissues in the high- and low-risk groups in TCGA. **(D)** Predicted proportions of ICB responders and non-responders among glioma patients with TERTp mutations in the high-risk and low-risk groups.

treatment option for glioma patients with TERTp mutations in the high-risk group (Figure 6D). Hence, we propose that glioma patients with TERTp mutations may benefit from the present risk model to guide their clinical treatment.

Validation of HOXC6, WT1, CD70, and OTP expression trends in glioma tissues with TERTp mutations

We next analyzed 54 glioma samples with TERTp mutations obtained in our institution, divided into long-term and short-term survival groups. Immunohistochemistry revealed higher expression

levels of HOXC6, WT1, CD70, and OTP in the long-term vs. the short-term survival group (Figure 7A, 7B). ROC analysis was subsequently applied to determine the significance of HOXC6, WT1, CD70, and OTP expression levels on patient survival. Results indicated a significant prognostic value for the four genes (AUC = 0.78, 0.09, 0.81, and 0.81, respectively) (Figure 7C–7F).

5-fluorouracil and gemcitabine may benefit high-risk glioma patients with TERTp mutations

In order to determine which oncology drugs might be appropriate for high-risk TERTp-mutant glioma




Figure 7. Expression of HOXC6, WT1, CD70, and OTP in 54 glioma cases with TERTp mutations. TERTp-mutant glioma samples from 54 glioma patients admitted to our hospital were divided into long- and short-term survival groups based on a survival cut-off of 15 months. (A) IHC scores for HOXC6, WT1, CD70, and OTP expression in glioma samples from patients in the long- and short-term survival groups. (B) Representative IHC images showing the expression of HOXC6, WT1, CD70, and OTP in glioma samples from the long- and short-term survival groups. (C–F) Diagnostic value of HOXC6, WT1, CD70, and OTP for distinguishing long- and short-term survivors among glioma patients with TERTp mutations.

patients, we integrated the corresponding gene expression profiles into a drug sensitivity matrix using the OncoPredict algorithm. Among 198 candidate drugs, higher sensitivity was predicted for 5-fluorouracil and gemcitabine for this subgroup of patients (Figure 8A–8C).

DISCUSSION

There is an urgent need for reliable prognostic models for patients with glioblastoma (GBM), the most common and aggressive primary brain tumor. Dysregulation of the immune microenvironment contributes to the progression of gliomas with TERTp mutations [13, 14]. In this work, our analysis of the TCGA-glioma patient cohort exhibiting TERTp mutations showed that patients with high stromal/immune scores had lower survival rates than those with low stromal/immune scores. Upon identification of DEGs between high and low stromal/immune score

groups, 73 out of 213 DEGs shared between the high stromal and high immune score groups were obviously correlated with prognosis. In turn, PPI network analysis revealed significant interactions (and prominent enrichment in cytokine signaling pathways) for 71 out of the 213 common DEGs. After LASSO and Cox regression analysis, immune profiles were established based on HOXC6, WT1, CD70, and OTP expression levels. Focusing on the TERTp-mutant glioma subtype, we developed an immune-related gene signature including HOXC6, WT1, CD70, and OTP that showed significant prognostic value for TERTp-mutant gliomas, but not for TERTp wild-type gliomas, in two TCGA cohorts. We thus suggest that TERTp-mutant gliomas may be appropriately assessed based on the present risk model.

Homeobox genes, mainly represented by the HOX gene family, act as critical developmental regulators by influencing cell proliferation, migration, differentiation,




Figure 8. Drug sensitivity analysis for high-risk TERTp-mutant gliomas. (A–C) OncoPredict analysis of drug sensitivity of TERTp-mutant gliomas. Results suggest higher sensitivity to 5-fluorouracil and gemcitabine therapies for glioma patients in the high- vs. the low-risk group. *** $P < 0.001$.

and death during axial patterning [15, 16]. HOXC6 was found to be overexpressed in clinical glioma samples, and its knockdown stimulated the WIF-1/Wnt signaling pathway and induced cell cycle arrest and apoptosis in U87 glioma cells [17]. HOXC6 was also found to regulate EMT signaling, and was proposed as a new immunotherapeutic target for gliomas [18, 19]. The orthopedia homeobox (OTP) gene, a member of the homeodomain (HD) family, plays an essential role in development and cell-fate specification of the hypothalamic neuroendocrine system in vertebrates [20]. OTP was identified as a reliable prognostic indicator in lung carcinomas, including neuroendocrine ones [21, 22]. CD70 is a costimulatory molecule involved in T-cell-mediated immunity that critically contributes to recurrent GBM aggressiveness and maintenance [23, 24]. Jin et al. reported that CD70-specific CAR T cells recognize primary CD70+ GBM tumors *in vitro* and mediate the regression of established GBM in xenograft and syngeneic rodent models [25]. Initially identified as a tumor suppressor, the Wilms' tumor 1 (WT1) gene has been shown to display significant increases in expression across a range of human cancers, including lung and pancreatic cancer [26, 27]. In turn, high levels of WT1 mRNA have been reported in gliomas at advanced clinical stages and with poor prognoses [28, 29].

The tumor microenvironment (TME) consists of different types of cells, including cancer cells, immune/inflammatory cells, vascular cells, and cancer-associated fibroblasts [30]. The progression of gliomas is influenced by immune cells that infiltrate the TME [31]. Glioma-associated macrophages predominantly exhibit the M2 phenotype, which induces angiogenesis and thus enhances tumor aggressiveness. We found that higher levels of naïve B cells, plasma cells, naïve CD4 T cells, and activated mast cells were characteristic of TERTp-mutant glioma patients with high-risk scores in both TCGA cohorts, in association with a lower survival rate. This evidence would suggest an immunosuppressive TME in TERTp-mutant glioma patients with high-risk scores.

Some patients with diverse cancer types, including bladder and lung cancer, have experienced significant benefits from ICB therapies [32, 33]. In these approaches, cancer cells can be killed by blocking immune checkpoints to reactivate deactivated immune cells [34]. There is, however, limited evidence that ICB is effective in gliomas with TERTp mutations. Our TIDE analysis indicated that ICB may improve the prognosis of TERTp-mutant glioma patients in the high-risk score group. Through further OncoPredict analysis, four candidate drugs, among them 5-fluorouracil and gemcitabine, were identified as potentially effective in this group. This evidence may contribute to guiding

chemotherapy and targeted therapies for high-risk glioma patients with TERTp mutations.

In conclusion, an immune signature based on HOXC6, WT1, CD70, and OTP expression was shown to serve as an independent and specific prognostic indicator for patients with TERTp-mutant gliomas. Interestingly, the high-risk population classified by this signature was predicted to benefit from ICB. This novel 4-gene, immune-related signature might thus be valuable to guide the treatment of gliomas with TERTp mutations.

MATERIALS AND METHODS

Gene expression profiling and estimation of immune and stromal scores

The TCGA genome database was accessed to obtain gene expression profiles from glioma patients. Several probe names were annotated as gene names, and raw gene expression profiles were normalized and centralized. Cases with mutations in the TERTp and those without survival data were excluded from the analysis. In the TCGA cohort, 155 patients had TERTp mutations and 166 patients were TERTp-wild-type. The ESTIMATE R tool was used to calculate immune and stromal scores in glioma tissues harboring TERTp mutations.

Analysis of differentially expressed genes

A significance threshold of $P < 0.05$ and $|\log\text{Fold-Change}| < 1$ was set to analyze differentially expressed genes (DEGs). Volcano plots were created to visualize and analyze gene expression changes in the high and low immune and stromal score groups, while heat maps were used to visualize DEGs.

Enrichment analysis

The Database for Annotation, Visualization and Integrated Discovery (DAVID) was used to analyze enriched KEGG and GO terms for hub genes. GO analysis was based on the three root categories: biological process (BP), cellular component (CC), and molecular function (MF). According to the significance threshold of $P < 0.05$, bubble plots were generated to display the top five terms.

Construction and verification of immune signatures

Immune signatures were first constructed by analyzing through univariate Cox regression those genes significantly related to survival in patients with TERTp mutations. By adding a penalty function (λ), LASSO was used to eliminate redundant genes. Using the Akaike information criterion, multivariate

Cox regression analysis was performed to develop a model for prognostic risk scoring. Risk scores were limited to 10 points. Kaplan-Meier survival analysis and ROC analysis were used to assess the prognostic accuracy of the risk model for glioma patients with mutant and wild-type TERTp.

Immune cell analysis

The R package CIBERSORT was used to investigate the presence of 22 tumor-infiltrating immune cell types in TCGA-glioma cases with TERTp mutations. An unpaired *t*-test with significance set at $P < 0.05$ was used to compare immune cell distribution between high-risk and low-risk groups.

Immunohistochemistry

From Guizhou Medical University Affiliated Hospital, 54 TERTp-mutant glioma tissues were collected prior to radiotherapy or chemotherapy, with approval from the Human Ethics Committee of Guizhou Medical University. All participants provided informed consent. The Human Research Ethics Review Committee of Guizhou Medical University approved the analysis of these clinical samples, which was carried out on basis of the tenets expressed in the Declaration of Helsinki. For immunohistochemistry (IHC), the sections were probed with the following antibodies: HOXC6 (1:200; ab41587; Abcam, Cambridge, UK), WT1 (1:100; 12609-1-AP, Proteintech, Wuhan, China), CD70 (1:500; 67749-1-Ig; Proteintech, Wuhan, China), and OTP (1:4000; ab254267; Abcam, Cambridge, UK).

Immunotherapy response prediction and drug sensitivity analysis

The online tool TIDE (Tumor Immune Dysfunction and Exclusion) was used to predict potential ICB responses [35]. *In vivo* drug responses were predicted using OncoPredict, an algorithm developed by Maeser et al. [36]. In order to calculate the sensitivity to drugs of gliomas, OncoPredict scripts were used to match the gene expression matrix of each glioma sample to the antitumor effects of drugs in cancer cells recorded in the Cancer Cell Line Encyclopedia (Broad Institute, Cambridge, MA, USA). Patients with gliomas with high drug scores are less sensitive to anticancer drugs. The limma package was used to analyze differences in drug scores between patients at high and low risk, while $|\log_{2}FC| \geq 1$, and adjusted $P < 0.05$ were set as cut-offs for significance.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

AUTHOR CONTRIBUTIONS

Wenpeng Cao and Shan Lei designed the experiments and wrote the manuscript; Jinzhi Lan, Zhirui Zeng, Chujiao Hu, Jinping Kong, and Yating Sun prepared Figures 1–4; Wenpeng Cao, Shan Lei, Zhixue Zhang, and Limin Xiang prepared Figures 5–8. The final version of the manuscript was reviewed by all of the authors, and they granted their approval.

CONFLICTS OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

ETHICAL STATEMENT AND CONSENT

The Human Research Ethics Review Committee of Guizhou Medical University approved the use of the 54 TERTp-mutant glioma samples (Approval No.: 2022-42), and analyses were conducted in compliance with the Declaration of Helsinki. All participants provided informed consent for sample collection before they were given radiotherapy or chemotherapy. All participants have agreed to publish this manuscript.

FUNDING

This study was supported by Department of Science and Technology of Guizhou Province (Guizhou Science and Technology Foundation (2020)1Y092), Department of Education of Guizhou Province (Guizhou Teaching and Technology (2023) 015), the National Natural Science Foundation of China (82160665), Department of Education of Guizhou Province (General (2022) 194), the Basic Research Program of the Guizhou Province Technology Bureau (ZK (2021) General-568), the Family Planning Commission of Guizhou Province (gzwkj2021-442).

REFERENCES

1. De Silva MI, Stringer BW, Bardy C. Neuronal and tumorigenic boundaries of glioblastoma plasticity. *Trends Cancer*. 2023; 9:223–36. <https://doi.org/10.1016/j.trecan.2022.10.010> PMID:36460606
2. Nicholson JG, Fine HA. Diffuse Glioma Heterogeneity and Its Therapeutic Implications. *Cancer Discov*. 2021; 11:575–90. <https://doi.org/10.1158/2159-8290.CD-20-1474> PMID:33558264
3. Nejo T, Yamamichi A, Almeida ND, Goretsky YE, Okada H. Tumor antigens in glioma. *Semin Immunol*.

- 2020; 47:101385.
<https://doi.org/10.1016/j.smim.2020.101385>
PMID:[32037183](https://pubmed.ncbi.nlm.nih.gov/32037183/)
4. Sun Z, Zhao Y, Wei Y, Ding X, Tan C, Wang C. Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune infiltration in glioblastoma. *Front Immunol.* 2022; 13:939523.
<https://doi.org/10.3389/fimmu.2022.939523>
PMID:[36091049](https://pubmed.ncbi.nlm.nih.gov/36091049/)
 5. McAleenan A, Jones HE, Kernohan A, Robinson T, Schmidt L, Dawson S, Kelly C, Spencer Leal E, Faulkner CL, Palmer A, Wragg C, Jefferies S, Brandner S, et al. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. *Cochrane Database Syst Rev.* 2022; 3:CD013387.
<https://doi.org/10.1002/14651858.CD013387.pub2>
PMID:[35233774](https://pubmed.ncbi.nlm.nih.gov/35233774/)
 6. Fujimoto K, Arita H, Satomi K, Yamasaki K, Matsushita Y, Nakamura T, Miyakita Y, Umehara T, Kobayashi K, Tamura K, Tanaka S, Higuchi F, Okita Y, et al. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. *Acta Neuropathol.* 2021; 142:323–38.
<https://doi.org/10.1007/s00401-021-02337-9>
PMID:[34148105](https://pubmed.ncbi.nlm.nih.gov/34148105/)
 7. Thomas C, Thierfelder F, Träger M, Soschinski P, Mütter M, Edelmann D, Förster A, Geiler C, Kim HY, Filipski K, Harter PN, Schittenhelm J, Eckert F, et al. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma. *Acta Neuropathol.* 2021; 141:959–70.
<https://doi.org/10.1007/s00401-021-02300-8>
PMID:[33755803](https://pubmed.ncbi.nlm.nih.gov/33755803/)
 8. Dratwa M, Wysoczańska B, Łacina P, Kubik T, Bogunia-Kubik K. TERT-Regulation and Roles in Cancer Formation. *Front Immunol.* 2020; 11:589929.
<https://doi.org/10.3389/fimmu.2020.589929>
PMID:[33329574](https://pubmed.ncbi.nlm.nih.gov/33329574/)
 9. Olympios N, Gilard V, Marguet F, Clatot F, Di Fiore F, Fontanilles M. TERT Promoter Alterations in Glioblastoma: A Systematic Review. *Cancers (Basel).* 2021; 13:1147.
<https://doi.org/10.3390/cancers13051147>
PMID:[33800183](https://pubmed.ncbi.nlm.nih.gov/33800183/)
 10. Appin CL, Brat DJ. Biomarker-driven diagnosis of diffuse gliomas. *Mol Aspects Med.* 2015; 45:87–96.
<https://doi.org/10.1016/j.mam.2015.05.002>
PMID:[26004297](https://pubmed.ncbi.nlm.nih.gov/26004297/)
 11. Guterres AN, Villanueva J. Targeting telomerase for cancer therapy. *Oncogene.* 2020; 39:5811–24.
<https://doi.org/10.1038/s41388-020-01405-w>
PMID:[32733068](https://pubmed.ncbi.nlm.nih.gov/32733068/)
 12. Chen C, Han S, Meng L, Li Z, Zhang X, Wu A. TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas. *PLoS One.* 2014; 9:e100297.
<https://doi.org/10.1371/journal.pone.0100297>
PMID:[24937153](https://pubmed.ncbi.nlm.nih.gov/24937153/)
 13. Gao M, Lin Y, Liu X, Zhao Z, Zhu Z, Zhang H, Ban Y, Bie Y, He X, Sun X, Zhang S. TERT Mutation Is Accompanied by Neutrophil Infiltration and Contributes to Poor Survival in Isocitrate Dehydrogenase Wild-Type Glioma. *Front Cell Dev Biol.* 2021; 9:654407.
<https://doi.org/10.3389/fcell.2021.654407>
PMID:[33996815](https://pubmed.ncbi.nlm.nih.gov/33996815/)
 14. Mondia MWL, Kritselis MA, Donahue JE, Elinzano H, Sarangi S, Bryant D, Capelletti M, Korn WM, Yu E, Yan S, Toms SA, Wong ET. Dimorphic glioblastoma with glial and epithelioid phenotypes: Clonal evolution and immune selection. *Front Neurol.* 2023; 13:1017087.
<https://doi.org/10.3389/fneur.2022.1017087>
PMID:[36703629](https://pubmed.ncbi.nlm.nih.gov/36703629/)
 15. Jimenez-García MP, Lucena-Cacace A, Otero-Albiol D, Carnero A. Regulation of sarcomagenesis by the empty spiracles homeobox genes EMX1 and EMX2. *Cell Death Dis.* 2021; 12:515.
<https://doi.org/10.1038/s41419-021-03801-w>
PMID:[34016958](https://pubmed.ncbi.nlm.nih.gov/34016958/)
 16. Rudzińska M, Czarnocka B. The Impact of Transcription Factor Prospero Homeobox 1 on the Regulation of Thyroid Cancer Malignancy. *Int J Mol Sci.* 2020; 21:3220.
<https://doi.org/10.3390/ijms21093220>
PMID:[32370142](https://pubmed.ncbi.nlm.nih.gov/32370142/)
 17. Yan TF, Wu MJ, Xiao B, Hu Q, Fan YH, Zhu XG. Knockdown of HOXC6 inhibits glioma cell proliferation and induces cell cycle arrest by targeting WIF-1 in vitro and vivo. *Pathol Res Pract.* 2018; 214:1818–24.
<https://doi.org/10.1016/j.prp.2018.09.001>
PMID:[30228024](https://pubmed.ncbi.nlm.nih.gov/30228024/)
 18. Eryi S, Zheng L, Honghua C, Su Z, Han X, Donggang P, Zhou Z, Liping Z, Bo C. HOXC6 Regulates the Epithelial-Mesenchymal Transition through the TGF-β/Smad Signaling Pathway and Predicts a Poor Prognosis in Glioblastoma. *J Oncol.* 2022; 2022:8016102.
<https://doi.org/10.1155/2022/8016102>
PMID:[35571491](https://pubmed.ncbi.nlm.nih.gov/35571491/)

19. Huang H, Huo Z, Jiao J, Ji W, Huang J, Bian Z, Xu B, Shao J, Sun J. HOXC6 impacts epithelial-mesenchymal transition and the immune microenvironment through gene transcription in gliomas. *Cancer Cell Int.* 2022; 22:170.
<https://doi.org/10.1186/s12935-022-02589-9>
PMID:35488304
20. Simeone A, D'Apice MR, Nigro V, Casanova J, Graziani F, Acampora D, Avantaggiato V. Orthopedia, a novel homeobox-containing gene expressed in the developing CNS of both mouse and *Drosophila*. *Neuron.* 1994; 13:83–101.
[https://doi.org/10.1016/0896-6273\(94\)90461-8](https://doi.org/10.1016/0896-6273(94)90461-8)
PMID:7913821
21. Hanley KZ, Dureau ZJ, Cohen C, Shin DM, Owonikoko TK, Sica GL. Orthopedia homeobox is preferentially expressed in typical carcinoids of the lung. *Cancer Cytopathol.* 2018; 126:236–42.
<https://doi.org/10.1002/cncy.21969>
PMID:29316326
22. Swartz DR, Henfling ME, Van Neste L, van Suylen RJ, Dingemans AM, Dinjens WN, Haesevoets A, Rudelius M, Thunnissen E, Volante M, Van Criekinge W, van Engeland M, Ramaekers FC, Speel EJ. CD44 and OTP are strong prognostic markers for pulmonary carcinoids. *Clin Cancer Res.* 2013; 19:2197–207.
<https://doi.org/10.1158/1078-0432.CCR-12-3078>
PMID:23444222
23. Seyfrid M, Maich WT, Shaikh VM, Tatari N, Upreti D, Piyasena D, Subapanditha M, Savage N, McKenna D, Mikolajewicz N, Han H, Chokshi C, Kuhlmann L, et al. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment. *J Immunother Cancer.* 2022; 10:e003289.
<https://doi.org/10.1136/jitc-2021-003289>
PMID:35017149
24. Ge H, Mu L, Jin L, Yang C, Chang YE, Long Y, DeLeon G, Deleyrolle L, Mitchell DA, Kubilis PS, Lu D, Qi J, Gu Y, et al. Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM. *Int J Cancer.* 2017; 141:1434–44.
<https://doi.org/10.1002/ijc.30830>
PMID:28612394
25. Jin L, Ge H, Long Y, Yang C, Chang YE, Mu L, Sayour EJ, De Leon G, Wang QJ, Yang JC, Kubilis PS, Bao H, Xia S, et al. CD70, a novel target of CAR T-cell therapy for gliomas. *Neuro Oncol.* 2018; 20:55–65.
<https://doi.org/10.1093/neuonc/nox116>
PMID:28651374
26. Wang W, Wang J, Yang C, Wang J. MicroRNA-216a targets WT1 expression and regulates KRT7 transcription to mediate the progression of pancreatic cancer-A transcriptome analysis. *IUBMB Life.* 2021; 73:866–82.
<https://doi.org/10.1002/iub.2468>
PMID:33759343
27. Wu Z, Qiu M, Mi Z, Meng M, Guo Y, Jiang X, Fang J, Wang H, Zhao J, Liu Z, Qian D, Yuan Z. WT1-interacting protein inhibits cell proliferation and tumorigenicity in non-small-cell lung cancer via the AKT/FOXO1 axis. *Mol Oncol.* 2019; 13:1059–74.
<https://doi.org/10.1002/1878-0261.12462>
PMID:30690883
28. Chiba Y, Hashimoto N, Tsuboi A, Rabo C, Oka Y, Kinoshita M, Kagawa N, Oji Y, Sugiyama H, Yoshimine T. Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients. *Brain Tumor Pathol.* 2010; 27:29–34.
<https://doi.org/10.1007/s10014-010-0265-9>
PMID:20425045
29. Yokota C, Kagawa N, Takano K, Chiba Y, Kinoshita M, Kijima N, Oji Y, Oka Y, Sugiyama H, Tsuboi A, Izumoto S, Kishima H, Hashimoto N. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy. *Cancer Immunol Immunother.* 2022; 71:189–201.
<https://doi.org/10.1007/s00262-021-02954-z>
PMID:34089373
30. Xiao Z, Dai Z, Locasale JW. Metabolic landscape of the tumor microenvironment at single cell resolution. *Nat Commun.* 2019; 10:3763.
<https://doi.org/10.1038/s41467-019-11738-0>
PMID:31434891
31. Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. *Nat Neurosci.* 2016; 19:20–7.
<https://doi.org/10.1038/nn.4185>
PMID:26713745
32. Chen X, Xu R, He D, Zhang Y, Chen H, Zhu Y, Cheng Y, Liu R, Zhu R, Gong L, Xiao M, Wang Z, Deng L, Cao K. CD8⁺ T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer. *Oncogene.* 2021; 40:6223–34.
<https://doi.org/10.1038/s41388-021-02019-6>
PMID:34552192
33. Zhou F, Qiao M, Zhou C. The cutting-edge progress of immune-checkpoint blockade in lung cancer. *Cell Mol Immunol.* 2021; 18:279–93.
<https://doi.org/10.1038/s41423-020-00577-5>
PMID:33177696

34. Chowell D, Yoo SK, Valero C, Pastore A, Krishna C, Lee M, Hoen D, Shi H, Kelly DW, Patel N, Makarov V, Ma X, Vuong L, et al. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. *Nat Biotechnol.* 2022; 40:499–506.
<https://doi.org/10.1038/s41587-021-01070-8>
PMID:[34725502](https://pubmed.ncbi.nlm.nih.gov/34725502/)
35. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman GJ, Brown MA, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. *Nat Med.* 2018; 24:1550–8.
<https://doi.org/10.1038/s41591-018-0136-1>
PMID:[30127393](https://pubmed.ncbi.nlm.nih.gov/30127393/)
36. Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. *Brief Bioinform.* 2021; 22:bbab260.
<https://doi.org/10.1093/bib/bbab260>
PMID:[34260682](https://pubmed.ncbi.nlm.nih.gov/34260682/)

SUPPLEMENTARY MATERIALS

Supplementary Tables

Please browse Full Text version to see the data of Supplementary Table 1.

Supplementary Table 1. List of co-upregulated and co-downregulated genes in TERTp-mutated gliomas in the high immune and high stromal groups.

Supplementary Table 2. The hazard rate of genes for glioma patients with TERT promoter-mutated.

ID	HR	HR.95L	HR.95H	p-value
IL10	1.401296707	1.16820136	1.680902392	2.78E-04
CD80	1.680121477	1.31873489	2.140542577	2.68E-05
CXCR3	1.673062748	1.311257916	2.134697472	3.48E-05
HOXA5	1.311948358	1.193513819	1.44213537	1.85892E-08
CD40LG	1.683021846	1.324759093	2.1381718	2.02E-05
IL2RA	1.263449436	1.085284275	1.470862993	2.57E-03
FCGR2A	1.570908668	1.242643354	1.985890831	1.59E-04
CD3D	1.416891407	1.188753932	1.688811456	0.000100121
HOXC6	1.339777582	1.191359826	1.506684992	1.05E-06
HAND2	1.308185324	1.170750093	1.46175418	2.10E-06
HOXA7	1.264175956	1.166146986	1.370445464	1.25E-08
HOXA10	1.263760788	1.165656311	1.370121977	1.36E-08
HOXB4	1.256479211	1.137275368	1.388177438	7.15E-06
KLRB1	1.317327982	1.082842817	1.602589947	5.86E-03
HOXA11	1.263335609	1.149044264	1.388995106	1.35E-06
HOXA4	1.253359993	1.154319813	1.36089778	7.57E-08
HOXA6	1.374021361	1.217284587	1.550939461	2.72E-07
HOXB5	1.402434859	1.199381587	1.639864707	2.25E-05
PTPN22	1.612489649	1.336986502	1.944763739	5.79E-07
CCL20	1.322543716	1.153477064	1.51639069	6.18E-05
CCR2	1.440138364	1.193514248	1.73772413	1.41E-04
EOMES	2.162706032	1.564438559	2.989760993	3.03E-06
HOXA3	1.300062396	1.187452601	1.423351325	1.37E-08
ICOS	1.8048284	1.412505119	2.306119469	2.34E-06
SHOX2	1.223249578	1.110456152	1.347499879	4.45E-05
AFP	1.562430931	1.248837288	1.954770599	9.46E-05
CD3G	1.891114604	1.449651399	2.467016861	2.63E-06
GATA4	1.307196099	1.145094066	1.492245652	7.32E-05
HLA-DQB2	1.333241464	1.123164091	1.582611851	1.01E-03
HOXA2	1.283245686	1.17444172	1.402129592	3.45E-08
HOXB6	1.278199257	1.080801373	1.511649949	4.13E-03
SLAMF1	1.817295749	1.404517107	2.351387407	5.52E-06
TREM1	1.262565437	1.127167166	1.414228103	5.62E-05
CLEC12A	1.341744641	1.140699448	1.578223506	3.86E-04
HOXA9	1.225208849	1.121304557	1.338741302	7.05E-06
HOXB2	1.297325529	1.169681194	1.438899367	8.40E-07
HOXD10	1.36713449	1.215792098	1.537316057	1.75E-07
NKX2-5	1.244500417	1.122792335	1.379401373	3.10E-05

WT1	1.300897745	1.158758861	1.460472062	8.35E-06
CD300LB	1.520548159	1.199903031	1.926877959	0.000524043
EMR1	1.426187179	1.192978147	1.704985021	9.74366E-05
GZMK	1.482573876	1.213433795	1.811409329	0.000116823
HOXC10	1.2943038	1.176692782	1.423670097	1.11153E-07
HOXC13	1.376912665	1.231280801	1.539769389	2.04992E-08
HOXC8	1.220296021	1.104497377	1.348235324	9.08623E-05
HOXC9	1.381213083	1.212463096	1.573449606	1.18776E-06
HOXD11	1.358327605	1.210728902	1.523919913	1.80763E-07
HOXD13	1.311717864	1.188299062	1.447955158	7.3699E-08
HOXB3	1.274676411	1.160273371	1.400359599	4.22954E-07
HOXB8	1.247854698	1.098546631	1.417455849	0.000660481
HOXC11	1.375777433	1.222296182	1.548531014	1.2504E-07
HOXD9	1.358154675	1.201031583	1.535833153	1.05995E-06
TRAT1	2.167431523	1.633716898	2.875503958	8.17295E-08
UBASH3A	1.817028631	1.388515496	2.377786246	1.35017E-05
CD70	1.642563121	1.332438182	2.024869628	3.3466E-06
CXCL6	1.257642315	1.101595506	1.435793976	0.000695177
FOXD3	1.208852224	1.014229337	1.440821761	0.034198992
IDO1	1.305190356	1.105804698	1.540526883	0.001638069
KRT7	1.320853258	1.135029896	1.537099011	0.000321571
PAX3	1.326831526	1.174648712	1.498730539	5.37224E-06
ZNF683	1.578651355	1.175757019	2.119604697	0.002389883
AREG	1.338353008	1.097220392	1.632478568	0.004036102
CEACAM4	1.341915123	1.027226522	1.753007889	0.031007269
CLEC5A	1.251684284	1.114414278	1.405862773	0.000152001
HOXA1	1.351151142	1.197873039	1.52404249	9.6411E-07
HOXA13	1.198591954	1.070500298	1.34201053	0.001681566
MMP7	1.198670225	1.054127433	1.363032839	0.005710016
OTP	1.552617782	1.345994136	1.790960238	1.56122E-09
POSTN	1.206300498	1.118697781	1.300763187	1.0832E-06
SAA1	1.190234398	1.100321451	1.287494596	1.38972E-05
SPAG17	1.370532233	1.187884542	1.581263613	1.56473E-05
TNFSF14	1.951613296	1.536187074	2.47938192	4.36635E-08
TREML2	1.556284703	1.200625914	2.017299517	0.000834258